Claims for Patent: 9,271,866

Summary for Patent: 9,271,866

Title:	Apparatus and methods for delivering therapeutic agents
Abstract:	In various embodiments, a drug-delivery device includes one or more reservoirs that may each contain a therapeutic agent for delivery to a patient.
Inventor(s):	Humayun; Mark S. (Glendale, CA), Caffey; Sean (Pasadena, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	13/931,074
Patent Claims:	1. A drug-delivery device, comprising: a refillable reservoir having a self-resealing upper layer that is pierceable by a needle for refilling and an opposed lower layer that is unpuncturable by the needle so as to protect an eye from injury, and containing a liquid that comprises a therapeutic agent selected from the group consisting of acetazolamide, betaxolol, bevacizumab, bimatoprost, brimonidine, brinzolamide, carbidopa, carteolol, cidofovir, cyclosporine, dorzolamide, epinephrine, a growth factor, irinotecan, ketorolac tromethamine, ketotifen fumarate, latanoprost, levobetaxolol, levobunolol, levodopa, levofloxacin, loratadine, loteprednol etabonate, metipranolol, naphazoline, ofloxacin, pegaptanib, pemirolast, pheniramine maleate, pilocarpine, pseudoephedrine, ranibizumab, a steroid, timolol, travoprost, trifluridine, tumor necrosis factor blocker, unoprostone isopropyl, valganciclovir, verteporfin, vitravene, a drug that prevents beta amyloid deposition in the retina, a drug that prevents beta amyloid deposition in the brain, an anti-human complement activation blocker that blocks complement H activation in the eye, and siRNA molecules; a cannula in fluid communication with the reservoir, the cannula having an outlet for delivering the therapeutic agent to a patient; a memory for storing a drug-delivery regimen; a microprocessor for executing the stored drug-delivery regimen; and a sensor for detecting a position and an activity of the patient, the microprocessor determining at least one of a frequency, time, or dosage of the liquid delivered to the patient based thereon and responsively controlling delivery of the liquid. 2. The device of claim 1, wherein the device is shaped to conform to a curved contour of the eye. 3. The device of claim 1, wherein the lower layer is implanted adjacent to the sclera of the eye and the cannula is inserted into the eye through the sclera to facilitate delivery of drug from the reservoir into the eye. 4. The device of claim 1, further comprising a sensor for receiving feedback from the patient, the microprocessor being configured to modify the drug-delivery regimen based on the feedback. 5. The device of claim 1, further comprising a sensor for detecting a measured eye pressure for the patient. 6. The device of claim 5, wherein the sensor monitors physiological effects of the therapeutic agent present for determining a residual amount of the therapeutic agent in a tissue of the patient. 7. The device of claim 1, further comprising a transceiver for receiving wireless instructions that reprogram the drug-delivery regimen. 8. The device of claim 1, further comprising: an electrolysis chamber including a gas-impermeable flexible membrane configured to expand and contract with increases and decreases in pressure in the electrolysis chamber, the flexible membrane also constituting a portion of the reservoir; and at least two electrodes in the electrolysis chamber, the electrodes being responsive to the microprocessor to produce gas in the electrolysis chamber to expand the membrane and thereby force liquid from the reservoir through the cannula. 9. The device of claim 1, further comprising a valve disposed in the cannula, wherein the valve controls fluid delivery, maintains a constant flow rate independent of variations in pressure driving a fluid flow through the cannula, and prevents backflow.

Details for Patent 9,271,866

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2027-12-20
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2027-12-20